Abstract 1
Isolation of PBG from plant material has been reported previously (9). As 1 experimental hosts, we used 8-week-old outbred male ICR mice (body weight, 20 ± 2 g) 2 purchased from Japan SLC (Hamamatsu, Japan). The animals were housed in standard 3 cages, provided with standard feed and water ad libitum, and acclimatized for 10 d prior to 4 the experiments. The malarial parasites used were of a chloroquine-sensitive strain of P. 5 berghei (ATCC 50175; American Type Culture Collection, Manassas, VA), which had 6 been maintained by serial blood passage in mice. The schizontocidal activity of PBG on 7 early P. berghei infection was evaluated in a "4-day" test (5). In this test, blood from an 8 infected donor mouse was diluted with isotonic saline to yield an inoculum containing 5 × 9 percentage parasitemia of the mice "treated" only with distilled water (the negative 2 1 controls) and B is the mean parasitemia in the test group. The possible "repository" activity 2 2
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on September 12, 2017 by guest http://aac.asm.org/ Downloaded from of PBG was assessed using the method described by Peters (7). For this, a further six 1 groups of mice (again with five mice/group) were respectively treated pre-infection with 2 0.2 ml oral doses of PBG in water (at 5, 10, or 25 mg·kg -1 ·d -1 ), pyrimethamine in water (at 3 1.2 mg·kg -1 ·d -1 ), or pure distilled water, for 4 consecutive days (days 0-3). On day 4, the 4 mice were inoculated with P. berghei (as in the 4-d test) and on day 7 (72 h post-infection) 5 their parasitemias were assessed. In order to evaluate the schizontocidal activity in 6 established infection (8), the 4-d test was repeated but modified so that the first treatment 7 did not take place until 72 h after the mice had been infected; the mice were treated daily 8 for 5 (not 4)-d and parasitemias were evaluated on each day of the treatment. In addition, 9 mortality and weight changes in the mice were followed up to 30 d post-infection (day 29), 1 0 and the day-29 parasitemias of the survivors were evaluated. The median lethal dose (LD 50 ) 1 1 of PBG, when administered intraperitoneally, was also determined, using uninfected ICR 1 2 mice and the method of Lorke (6). Data were compared using Student's t-tests. 1 3
In both the 4-d test and the test of "repository" activity, oral PBG produced dose-1 4 dependent chemosuppression (Table 1) , with even the lowest dose tested (5 mg·kg -1 ·d -1 ) 1 5 producing significant reductions in parasitemia (P < 0.05). The highest dose of PBG tested 1 6
(25 mg·kg -1 ·d -1 ) was not as effective as the lowest dose tested (5, or 10 mg·kg -1 ·d -1 ) and 1 7
did not achieve the level of chemosuppression seen with the drugs used as positive controls 1 8
-chloroquine at 5 mg·kg -1 ·d -1 or pyrimethamine at 1.2 mg·kg -1 ·d -1 (Table 1 ). The in vivo 1 9
antimalarial activity of PBG is presented in Fig. 2 . The procedure followed was that of the 2 0 classical 4-d suppressive test of Peters (7) in which the test compound is administered to The mice still alive on day 29 (all of which had been treated with PBG or chloroquine) 1 1
were aparasitemic. In the tests of activity against established infection, the highest tested 1 2 doses of PBG appeared as effective as chloroquine in terms of the day-7 parasitemias ( Fig.  1  3 2) and the day-29 survival. In the toxicity tests, all the mice administered PBG at 5-500·mg·kg -1 exhibited 1 7
insignificant signs of toxicity, ranging from writhing and gasping (LD 50 of >500 mg·kg -1 ) 1 8
to decreased respiratory rate, decreased limb tone, and death. The LD 50 was calculated to be 1 9 >500 mg·kg -1 , however, and none of the mice administered PBG in the tests of antimalarial 2 0 activity exhibited any signs of acute toxicity. 
